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Abstract
Background: Quality control (QC) is an essential part of 
clinical biochemistry to ensure that laboratory test results 
are reliable and correct. Those tests without a defined 
reference method constitute a special challenge, as is the 
case with bone-specific alkaline phosphatase (BAP).
Methods and Results: The present study reports an 
example where a shift in a BAP assay was detected by use 
of a patient pool and supported by a retrospective calcula-
tion of “patient mean”, while the external QC and specific 
assay control material were unaffected by the shift.
Conclusions: Patient pools and the use of patient means 
remain a useful and inexpensive procedure for internal QC.
Keywords: analytical bias; bone-specific alkaline phos-
phatase; patient means;  patient pool; quality control.
Introduction
For the clinical use of blood tests, it is essential that results 
are reliable and accurate, which is why quality control 
(QC) has become the cornerstone of clinical biochemistry. 
QC must be able to detect analytical errors that can poten-
tially lead to harm in patients [1–3].
Bone-specific alkaline phosphatase (BAP) is a bone 
formation marker frequently used in clinical trials of 
diseases that affect the bone, such as multiple myeloma 
and osteoporosis. However, bone markers are still not a 
part of daily clinical practice. One reason for this might 
be explained by the many different challenges concerning 
the analysis of serum BAP, including: no established refer-
ence method, a lack of available primary calibration mate-
rial [4] and a high degree of inter-method variation [5].
We recently discovered an analytical error due to a 
shift in an assay of serum BAP that was not detected by 
either the control material included in the assay or the 
external QC system, but was brought to our attention by 
the use of a patient pool (PP). This demonstrates that 
analytical errors can sometimes be difficult to detect and 
highlights the importance of a multi-tiered QC system.
Materials and methods
Samples of a PP are routinely used as part of the internal QC for a 
number of biochemical tests at the Department of Immunology 
and Biochemistry, Lillebaelt Hospital, Denmark. During the analy-
sis of BAP, samples from the PP were used as part of the QC, as no 
independent control material was available. During autumn 2013, 
increasing values of serum BAP were noticed while analyzing the 
PP. Therefore, we decided to review the results, beginning retrospec-
tively from September 2009 and up to June 2014. This review sup-
ported the suggestion of a shift in the results of the assay. In order 
to investigate this further, the “patient mean” for each month was 
calculated over the same period.
Serum BAP was analyzed during the whole period with an 
immunoassay measuring enzyme activity (MicroVue BAP EIA, 
Quidel Corporation, San Diego, CA, USA). There was no change in 
the instructions for use of the assays from the manufacturer during 
the period. Eleven different lot numbers were used during the period. 
QC material was provided by the supplier of the assay and UK NEQAS 
was used as an external control throughout. In addition, tests were 
also exchanged with a Danish university hospital laboratory, from 
August 2013, using the same BAP assay.
The same PP was used throughout the study period. The PP was 
produced on 26 May, 2009 as a pool of residual serum from 125 to 150 
blood samples analyzed in the laboratory. After mixing, the material 
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was aliquoted and stored at −80 °C. Every time the serum BAP test 
was run, a double determination of the PP was made. Once during 
the study period we adjusted the limits of the PP. The mean values of 
serum BAP of the PP were calculated for each month. The monthly 
patient median was calculated for illustrative purposes as shown in 
Figure 1.
The standard pre-analytical handling of the test material in the 
laboratory remained unchanged throughout the period.
Results
From September 2009 until August 2010 the PP and patient 
mean remained stable and provided a baseline level. 
However, from September 2010 to October 2011 there was a 
slow but steady increase in the results from analysis of the 
PP, after which they stabilized to a level approximately 25% 
above the baseline level. In the subsequent period from 
October 2011 to June 2012, the stability was maintained, 
but then a continuous increase in results from the PP, as 
well as patient mean was seen until August 2013 where it 
reached a level of 100% above the baseline level of 2009.
In December 2013, the level suddenly dropped to the 
baseline found in 2009 as a 50% decrease in the level of 
the PP was observed. This level was maintained until end 
of the observation period (Figure 1).
The mean number of serum BAP patient tests per-
formed was 75 (10–210) per month, which fell to a mean 
of 26 (10–72) tests per month between February 2013 and 
June 2014.
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Figure 1: Bone-specific alkaline phosphatase (BAP) patient values 
in patient pool, “patient mean” and “patient median”.
BAP levels measured in the PP (black), the calculated “patient 
mean” (gray) and the calculated “patient median” (light gray). The 
mean of the PP, the “patient mean” and the “patient median” were 
calculated monthly. Note: the steady increase from September 2010 
and the marked decrease in December 2013.
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Figure 2: Results of the quality control material provided by the 
supplier.
Test results from the high (gray) and low (gray) control material was 
within their respective control limits (black), and did not indicate 
any problems with the assay. The quality control material from the 
supplier is specific for each lot number and therefore do the control 
limits vary during the period.
All analyses performed on QC material provided by 
the supplier successfully passed the control test (Figure 2). 
The external QC, carried out by participation in the assess-
ment program from UK NEQAS, also showed acceptable 
results throughout the study period. The samples that 
were exchanged with another Danish laboratory using the 
same assay also recognized the dramatic decrease in the 
BAP levels in autumn 2013.
Discussion
PP prepared of human serum has long been known as a 
useful and inexpensive control material [6].
For the analysis of BAP we used the PP as QC, in addi-
tion to the control material supplied by the manufacturer 
as no third party control material was available [7].
However, stability of the measured biochemical 
marker is essential for the use of PP as QC. The exact long-
term stability of BAP in our pool is not known, but main-
tained stability of biochemical markers in serum pools 
stored at −80 °C for more than five years has been reported, 
however, BAP was not included in this study [8]. Others 
have found BAP to be stable for one year [9], while a study 
investigating the stability of several biochemical markers 
including alkaline phosphatase demonstrated that most 
of the analyses showed variability over time, especially 
Brought to you by | University Library of Southern Denmark - Syddansk Universitetsbibliotek
Authenticated
Download Date | 1/8/18 1:49 PM
Hinge et al.: Shift in BAP assay detected by use of patient pool      405
when new lot numbers were introduced. Nonetheless, the 
PP remained stable for the majority of parameters meas-
ured during the 13-month study period [10]. These studies 
support the long-term stability of PP and we do not believe 
that the shift in the results found in our measurements of 
serum BAP is due to instability of our PP. This observa-
tion is also supported by the results of the patients mean 
which was calculated retrospectively.
Various methods of using patient data in labora-
tory QC have been described [11–13]. In a study testing 
the use of patient means, medians and “average of 
normals” as assessments for long-term analytical stabil-
ity, the authors demonstrated how the patient results of 
ammonia increased and revealed an inaccurate lot of 
the assay, while the normal control material consisting 
of an ammonium sulphate solution remained stable [14]. 
Our observations with BAP illustrate the same problem. 
We simply calculated the patient mean, which reinforce 
our suspicion of a shift in the BAP assay. The use of 
patient mean as a QC tool has its limitations as it is only 
sensitive to systematic errors and not random errors. 
The patient mean will also be affected by changes in the 
patient populations as well as being sensitive to outli-
ers especially, when working with limited test numbers. 
Even so, this method offers some advantage. By provid-
ing information about change, both in analytical and 
pre-analytical performance, the method can be used to 
detected instrument malfunction or assay error. Further-
more, it is a relatively inexpensive method and advances 
in computer software have resulted in reduced work 
load. The use of patient mean is also independent of any 
control material. However, given that BAP is not a fre-
quently used test, our calculation of patient mean relies 
on relatively few results which exposed a vulnerability 
to outliers with extremely high or low values. Calculat-
ing an average of normals to exclude extreme outliers 
using the median or a “moving mean”, could have mini-
mized that problem and might therefore be the preferred 
QC tool [12, 13, 15]. In line with this a recent publication 
stresses the usefulness of using patient data for moni-
toring analytical stability by calculations of the monthly 
medians of patient results [16]. Awareness of change 
in clinical practice for ordering a test or other change 
in the case-mix of patients may be important when 
using patient means as QC. Even though the number 
of measured serum BAP tests decreased toward the 
end of our study period, the patient case-mix remained 
unchanged. As such changes did not occur in our study 
we concluded that the calculation of the patient mean 
provided further evidence of an analytical error in the 
serum BAP assay.
One explanation for the failure of the UK NEQAS exter-
nal quality assessment program to detect the problem may 
be that our results were only compared with results from 
other laboratories that used assays from the same manu-
facturer. If the measurements from this assay had shifted 
over time toward increasingly higher levels, as we sus-
pected, all other participating laboratories using this par-
ticular assay should also have had a shift in their results 
over time. However, tests performed simultaneously in 
different laboratories all showed results of a consistently 
false high level. Consequently, the external control that 
was used only provides information about a laboratory’s 
handling of the analysis. As the used levels of BAP in the 
control tests are random and not fixed, it was not possible 
to identify a shift over time.
Within the external quality assessment program, 
there was no direct comparison made with the results 
from laboratories that used other methodologies as 
other units were used. In a recent published study, dif-
ferent serum BAP assays were compared and the Quidel 
MicroVue assay achieved the highest equivalent values 
[5].
The fact that the control material supplied with the 
assay did not detect the problem is of concern. One likely 
explanation for this failure could be that the production 
of control material might not have been totally independ-
ent of the calibrator and the assay. We also speculate that 
the sudden decrease in test results of serum BAP in the PP 
seen in December 2013, which corresponded to levels in 
2009, may represent a re-calibration.
We first notified the manufacturer of the assay with 
our observations in August 2013, and then in May 2014 
we submitted a written review of our worries concern-
ing the assay. The manufacturer did not agree that our 
observations could be explained by a shift in the BAP 
assay.
As seen in our results, the bias observed from the test 
kit may have started three years prior to our recognition of 
the problem. The subtle increase in values at the start may 
have contributed to the delay in recognition. However, 
once the limits for the PP were adjusted, we observed the 
first sign of an error. However, this error was not investi-
gated further at that time because there was no documen-
tation available on the stability of BAP in our pool. As a 
result, an assumption was made that the slow increase in 
BAP results of the pool could be explained by the insta-
bility of BAP in the pool. However, once the increase in 
test results of BAP in the pool accelerated, we reasoned 
that there must be another explanation, other than the 
instability of BAP in the pool. The sudden decrease in the 
BAP results of the pool, observed in December 2013, also 
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supported our assumption that the instability of BAP in 
the pool was not responsible for the steady increase in test 
results. Another factor contributing to our delay in rec-
ognizing the increase in BAP results may have been that 
BAP is not frequently tested and the test was only used for 
scientific purposes, and consequently not evaluated on 
regular basis by the clinicians. A routinely calculation of 
patient mean may probably have helped to recognize the 
problem sooner.
We have adjusted the test results of patients in clini-
cal protocols for the period September 2010 to November 
2013 using the PP as a reference. We believe this gives the 
best estimate for the exact value. No patients were harmed 
or adversely affected as a result of the inaccuracies iden-
tified, as BAP was solely used for research purposes. In 
conclusion, this study illustrates the need for an efficient 
multi-tiered QC system and for standardization and estab-
lishment of a primary reference method.
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